Firsty, PSMAddition (NCT04720157), an international, multicenter, open-label, randomized, phase III study investigating [177Lu]Lu-PSMA-617 combining with ADT in hormone naïve prostate cancer patients in comparison to standard of care. The gene discussed is FOLH1; the disease is prostate cancer.